Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Medtronic PLC (BVMF:MDTC34) (MDT) shares soared to a 52-week high of $93.12, marking a significant milestone for the $118 billion medical device giant. According to InvestingPro data, the stock has delivered an impressive 15.2% return year-to-date, while maintaining consistently low price volatility. The medical device company has seen its stock price climb steadily over the past year, culminating in this new peak. Investors have shown increased confidence in Medtronic (NYSE:MDT)’s growth prospects, with the stock delivering a 13.8% return over the past year. The company maintains a strong 3% dividend yield and has increased dividends for 11 consecutive years. This uptick is a testament to the company’s resilience and the successful execution of its strategic initiatives, which continue to drive shareholder value. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value, with analysts setting price targets ranging from $85 to $112. Discover 8 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Medtronic reported its third-quarter earnings for fiscal year 2025, with adjusted earnings per share (EPS) of $1.39, surpassing analyst expectations of $1.36. However, the company’s revenue of $8.29 billion fell short of forecasts, which anticipated $8.33 billion. This revenue miss was partly attributed to distributor de-stocking in the Surgical Innovations division, which accounts for about 25% of Medtronic’s sales. Despite the revenue shortfall, Medtronic remains optimistic, as the company expects this to be a temporary issue and anticipates a resolution by the start of fiscal year 2026.
In other developments, Medtronic received FDA approval for its BrainSense™ Adaptive deep brain stimulation system, marking a significant advancement in personalized treatment for Parkinson’s disease. This technology is expected to be available in the United States in the coming months. Meanwhile, UBS raised its price target for Medtronic to $95, maintaining a Neutral rating on the stock. This adjustment reflects the belief that concerns over Medtronic’s future financial guidance may be overstated.
Stifel analysts maintained a Hold rating on Medtronic with a price target of $87, noting the company’s mixed performance in the third quarter. They highlighted that despite some challenges, Medtronic’s management is confident in its core businesses and expects continued growth. The company has also reported strong growth in its Diabetes and Cardiac Ablation Solutions segments, driven by product innovations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.